Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)

Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients with chronic liver disease (CLD). Lusutrombopag, a small‐molecule, thrombopoietin (TPO) receptor agonist, was evaluated as a treatment to raise platelet counts (PCs) in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Peck‐Radosavljevic, Markus, Simon, Krzysztof, Iacobellis, Angelo, Hassanein, Tarek, Kayali, Zeid, Tran, Albert, Makara, Mihaly, Ben Ari, Ziv, Braun, Marius, Mitrut, Paul, Yang, Sheng‐Shun, Akdogan, Meral, Pirisi, Mario, Duggal, Ajay, Ochiai, Toshimitsu, Motomiya, Tomoko, Kano, Takeshi, Nagata, Tsutae, Afdhal, Nezam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849531/
https://www.ncbi.nlm.nih.gov/pubmed/30762895
http://dx.doi.org/10.1002/hep.30561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849531/
https://www.ncbi.nlm.nih.gov/pubmed/30762895
http://dx.doi.org/10.1002/hep.30561

Ejemplares similares